BACKGROUND: CD4-specific rates of mortality in sub-Saharan African adults with high CD4 counts have rarely been estimated. This estimation is useful to the when to start antiretroviral treatment (ART) debate. METHODS: We pooled data from National Agency for Research on AIDS and Viral Hepatitis (ANRS)-funded research cohorts or associated partners in West Africa. All HIV-infected adults (≥18 years) with available follow-up time off ART were eligible. We used a joint model to estimate CD4 count evolution. We estimated CD4-specific rates of mortality, loss-to-follow-up (LTFU) and ART initiation by dividing the number of first event by the follow-up time off ART within each CD4 category. RESULTS: Between 1996 and 2009, 2588 adults (80% women) from 5 cohorts in Cote d'Ivoire and Burkina Faso were followed off ART during 6862 person-years. In the 201-350, 351-500, 501-650, and >650 cells per cubic millimeter CD4 categories, mortality rates were: 3.0, 1.5, 0.4, 0.2 per 100 person-years; LTFU rates: 6.0, 4.6, 6.1, 6.0 per 100 person-years; and ART initiation rates: 18.1, 2.7, 0.5, 0.5 per 100 person-years, respectively. All estimates varied across cohorts; mortality rates were higher when rates of LFTU and ART initiation were lower; LTFU rates were 2-40 times higher than mortality rates. CONCLUSIONS: Among untreated West African adults with high CD4 counts, mortality and LTFU rates were substantial. Even when data are collected under research conditions, informative censoring due to ART initiation and LTFU could lead to significantly underestimate mortality figures.
BACKGROUND:CD4-specific rates of mortality in sub-Saharan African adults with high CD4 counts have rarely been estimated. This estimation is useful to the when to start antiretroviral treatment (ART) debate. METHODS: We pooled data from National Agency for Research on AIDS and Viral Hepatitis (ANRS)-funded research cohorts or associated partners in West Africa. All HIV-infected adults (≥18 years) with available follow-up time off ART were eligible. We used a joint model to estimate CD4 count evolution. We estimated CD4-specific rates of mortality, loss-to-follow-up (LTFU) and ART initiation by dividing the number of first event by the follow-up time off ART within each CD4 category. RESULTS: Between 1996 and 2009, 2588 adults (80% women) from 5 cohorts in Cote d'Ivoire and Burkina Faso were followed off ART during 6862 person-years. In the 201-350, 351-500, 501-650, and >650 cells per cubic millimeter CD4 categories, mortality rates were: 3.0, 1.5, 0.4, 0.2 per 100 person-years; LTFU rates: 6.0, 4.6, 6.1, 6.0 per 100 person-years; and ART initiation rates: 18.1, 2.7, 0.5, 0.5 per 100 person-years, respectively. All estimates varied across cohorts; mortality rates were higher when rates of LFTU and ART initiation were lower; LTFU rates were 2-40 times higher than mortality rates. CONCLUSIONS: Among untreated West African adults with high CD4 counts, mortality and LTFU rates were substantial. Even when data are collected under research conditions, informative censoring due to ART initiation and LTFU could lead to significantly underestimate mortality figures.
Authors: J W Mellors; A Muñoz; J V Giorgi; J B Margolick; C J Tassoni; P Gupta; L A Kingsley; J A Todd; A J Saah; R Detels; J P Phair; C R Rinaldo Journal: Ann Intern Med Date: 1997-06-15 Impact factor: 25.391
Authors: Nicolas Nagot; Amadou Ouangré; Abdoulaye Ouedraogo; Michel Cartoux; Pierre Huygens; Marie Christine Defer; Tarnagda Zékiba; Nicolas Meda; Philippe Van de Perre Journal: J Acquir Immune Defic Syndr Date: 2002-04-15 Impact factor: 3.731
Authors: Albert Minga; Christine Danel; Yao Abo; Lambert Dohoun; Dominique Bonard; Ali Coulibaly; Julien Duvignac; François Dabis; Roger Salamon; Xavier Anglaret Journal: Bull World Health Organ Date: 2007-02 Impact factor: 9.408
Authors: Didier K Ekouevi; André Inwoley; Besigin Tonwe-Gold; Christine Danel; Renaud Becquet; Ida Viho; François Rouet; François Dabis; Xavier Anglaret; Valériane Leroy Journal: AIDS Res Hum Retroviruses Date: 2007-12 Impact factor: 2.205
Authors: Andrew N Phillips; Brian Gazzard; Richard Gilson; Philippa Easterbrook; Margaret Johnson; John Walsh; Clifford Leen; Martin Fisher; Chloe Orkin; Jane Anderson; Deenan Pillay; Valerie Delpech; Caroline Sabin; Achim Schwenk; David Dunn; Mark Gompels; Teresa Hill; Kholoud Porter; Abdel Babiker Journal: AIDS Date: 2007-08-20 Impact factor: 4.177
Authors: Wim Delva; Jeffrey W Eaton; Fei Meng; Christophe Fraser; Richard G White; Peter Vickerman; Marie-Claude Boily; Timothy B Hallett Journal: PLoS Med Date: 2012-07-10 Impact factor: 11.069
Authors: Patrick H Maduna; Matt Dolan; Lwando Kondlo; Honey Mabuza; Judith N Dlamini; Mike Polis; Thabo Mnisi; Susan Orsega; Patrick Maja; Lotty Ledwaba; Thuthukile Molefe; Phumelele Sangweni; Lisette Malan; Gugu Matchaba; Paul Khabo; Greg Grandits; James D Neaton Journal: PLoS One Date: 2015-04-09 Impact factor: 3.240
Authors: Sergio Serrano-Villar; Félix Gutiérrez; Celia Miralles; Juan Berenguer; Antonio Rivero; Esteban Martínez; Santiago Moreno Journal: Open Forum Infect Dis Date: 2016-05-12 Impact factor: 3.835
Authors: Ben Masiira; Kathy Baisley; Billy N Mayanja; Patrick Kazooba; Dermot Maher; Pontiano Kaleebu Journal: Glob Health Action Date: 2014-01-15 Impact factor: 2.640
Authors: Bo Langhoff Hønge; Sanne Jespersen; Pernille Bejer Nordentoft; Candida Medina; David da Silva; Zacarias José da Silva; Lars Ostergaard; Alex Lund Laursen; Christian Wejse Journal: BMJ Open Date: 2013-10-25 Impact factor: 2.692